Research summary ·
Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review.
Written based on 1 research study on PubMed, searched on 3 Nov 2026.
What was studied
This systematic review looked at ectopic Cushing syndrome (ECS) caused by medullary thyroid carcinoma (MTC). ECS is a rare problem with too much cortisol. The authors searched PubMed and Web of Science to January 25, 2026. They found 99 published cases. They also described new patients from a center in Bucharest, Romania. These were analyzed apart from the review.
What they found
The mean age was 46.3 years. Most patients were male. Most cases were sporadic, 32 of 43 with genetic data. Of 90 cases with stage data, 48 had distant metastases. Thyroid surgery was the first step in 62 of 77 cases. High cortisol was hard to control. Removal of both adrenal glands was needed in 33 patients. For 12 of them it was a rescue after drugs failed. A few reported cases got selective RET inhibitors, such as selpercatinib. Each of these cases had rapid blood test and scan responses. Most of the Bucharest patients did not reach remission.
What it means for patients
The authors say ECS from MTC is exceptionally rare and causes much illness. They say its care is complex and often needs several kinds of therapy. They say selective RET inhibitors may control both the tumor and the cortisol excess. This is in RET-mutated disease.
Why it is not certain yet
The RET inhibitor data come only from case reports. There were only a few Bucharest cases. The review rests on published case reports. Case reports cannot show how common these results are.
Source
Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review.
PubMed · PMID 42780339We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Thyroid cancer publications